Advaxis

Advaxis is a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products for the treatment of cancer. The company's proprietary Lm-based antigen delivery technology utilizes live attenuated Listeria monocytogenes bacteria bioengineered to express cancer-specific antigens, stimulating the immune system to target and destroy cancer cells.

Advaxis's technology aims to harness the power of the patient's own immune system to fight cancer. The modified Listeria bacteria enter antigen presenting cells, such as dendritic cells, stimulating a broad, multi-faceted immune response, including T-cell activation and natural killer (NK) cell activity. This approach seeks to overcome some of the limitations of traditional cancer therapies by providing a personalized and durable immune response against tumors.

The company's research and development efforts have focused on several cancer types, including cervical cancer, anal cancer, prostate cancer, and head and neck cancer, with ongoing clinical trials evaluating the safety and efficacy of its immunotherapies. Advaxis has sought collaborations and partnerships to further develop and commercialize its products.